MIM
FULC icon

MetLife Investment Management’s Fulcrum Therapeutics FULC Stock Holding History

MetLife Investment Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$125K Buy
34,079
+915
+3% +$5.57K ﹤0.01% 2679
2026
Q1 		$254K Buy
33,164
+10,450
+46% +$96.9K ﹤0.01% 2098
2025
Q4 		$257K Sell
22,714
-3,181
-12% -$32.4K ﹤0.01% 2151
2025
Q3 		$238K Sell
25,895
-6,650
-20% -$48.1K ﹤0.01% 2218
2025
Q2 		$224K Buy
32,545
+15,010
+86% +$80.3K ﹤0.01% 2130
2025
Q1 		$50.5K Sell
17,535
-22,572
-56% -$82.9K ﹤0.01% 2690
2024
Q4 		$189K Buy
40,107
+23,792
+146% +$87.8K ﹤0.01% 2332
2024
Q3 		$58.2K Buy
16,315
+417
+3% +$3.09K ﹤0.01% 2741
2024
Q2 		$98.6K Buy
+15,898
New +$120K ﹤0.01% 2611
2023
Q2 		– Sell
-27,689
Closed -$78.9K – 2959
2023
Q1 		$78.9K Buy
27,689
+8,799
+47% +$78.8K ﹤0.01% 2645
2022
Q4 		$138K Hold
18,890
– – ﹤0.01% 2458
2022
Q3 		$153K Buy
+18,890
New +$135K ﹤0.01% 2453
2022
Q2 		– Sell
-15,001
Closed -$355K – 2876
2022
Q1 		$355K Buy
15,001
+5,446
+57% +$77.1K ﹤0.01% 1992
2021
Q4 		$169K Hold
9,555
– – ﹤0.01% 2160
2021
Q3 		$270K Buy
+9,555
New +$181K ﹤0.01% 1888
2020
Q3 		– Sell
-6,267
Closed -$115K – 2315
2020
Q2 		$115K Buy
+6,267
New +$98.7K ﹤0.01% 2190

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MetLife Investment Management's FULC Position: Q2 2026 in Review

MetLife Investment Management increased its Fulcrum Therapeutics (FULC) stake by 2.8% in Q2 2026, buying an estimated $5.57K and bringing the position to 34,079 shares worth $125K. The position accounts for ﹤0.01% of the portfolio, ranked #2679.

MetLife Investment Management first reported a position in FULC in Q2 2020 and has held it in 16 quarters since. The position peaked at $355K in Q1 2022. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • MetLife Investment Management held 34,079 shares of Fulcrum Therapeutics worth $125K as of Q2 2026.
  • MetLife Investment Management bought 915 Fulcrum Therapeutics shares in Q2 2026, an estimated $5.57K.
  • Fulcrum Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2679 holding.
  • MetLife Investment Management first reported a position in Fulcrum Therapeutics in Q2 2020 and has held it in 16 quarters since.
  • MetLife Investment Management's Fulcrum Therapeutics position peaked at $355K in Q1 2022.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.